Ginkgo Bioworks
DNA
11.06
-0.41
-3.57%
Ginkgo Bioworks
US · DNA
#3438 by market cap
11.06
-0.41
-3.57%
Live - 5344 symbols - heartbeat 544s ago
· 2026-10-08 10:00
Pre-market
10.92
-4.80%
After-hours
11.31
-1.40%
Overnight
11.46
-0.09%
- Market cap
- 744.78M
- P/E (TTM)i
- -2.21
- P/Bi
- 1.77
- EPSi
- -5.64
- Div yieldi
- 0.00%
- 52W posi
- 44%
Reader sentiment
Are you bullish or bearish on DNA?
Anonymous reader poll. Unscientific, not investment advice.
About Ginkgo Bioworks
Ginkgo Bioworks, Inc. is building a platform to enable customers to program cells as easily as we can program computers. Ginkgo’s platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo is also actively supporting a number of biosecurity efforts to respond to COVID-19, including vaccine manufacturing optimization, therapeutics discovery, and K-12 pooled testing.
- Founded
- 2008
- CEO
- Dr. Jason Kelly, PhD
- Employees
- 485
- Headquarters
- Boston, Massachusetts, United States of America
- Fiscal year end
- 12-31
- Website
- www.ginkgobioworks.com
Company profile
- Exchange
- US
- Symbol
- DNA
- Market-cap rank
- #3438
- Market cap
- 744.78M
- Float cap
- 551.65M
- Shares out
- 67.34M
- Float shares
- 49.88M
Sectors & themes
Quote time 2026-10-08 10:00:19 · For reference only, not investment advice and not tailored to your situation.